Carteolol, an antihypertensive beta-blocker with intrinsic sympathomimetic activity, reduces ECG evidence of left ventricular hypertrophy.
Effective treatment of chronic hypertension may be accompanied by a decrease, increase, or no change in the extent of LVH, depending on the pharmacologic properties of the antihypertensive agents employed. Unlike beta-adrenoceptor blockers without ISA, beta-adrenoceptor blockers with ISA have been reported to increase left ventricular mass despite favorable reductions in blood pressure. To assess further the potential effect of ISA on LVH, we retrospectively evaluated the effect of carteolol, a nonspecific beta-adrenoceptor antagonist with strong ISA, upon ECG evidence of LVH. In 12 patients with LVH, carteolol treatment for one year reduced mean arterial blood pressures from 120 +/- 2 mm Hg to 100 +/- 2 mm Hg and mean hypertrophy scores from 5.2 +/- 0.6 to 2.6 +/- 0.8. Therefore, ISA does not preclude the regression of ECG evidence of LVH during the treatment of hypertension.
Rosales
O R
OR
Medical Service, Veterans Administration Medical Center, New Orleans.
Sander
G E
GE
Roffidal
L
L
Given
M B
MB
Giles
T D
TD
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006332:Cardiomegaly / Q000209:etiology / Q000503:physiopathology*; D002354:Carteolol / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D012189:Retrospective Studies; D013566:Sympathomimetics / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D011412:Propanolamines; D013566:Sympathomimetics; D002354:Carteolol